enGene Therapeutics Inc. 8-K

What Happened enGene Therapeutics announced its financial results for the quarter ended April 30, 2026 (press release furnished as Exhibit 99.1) and disclosed a strategic restructuring approved June 14, 2026 to reduce headcount by approximately 50% to preserve cash while awaiting durability data and FDA interactions for its LEGEND pivotal cohort. The company also reported the resignation of CMO Dr. Hussein Sweiti effective June 14, 2026 and appointed board member Dr. William Grossman as Interim Chief Medical Officer effective June 15, 2026.

Key Details

• Workforce reduction: ~50% of employees; Board approved restructuring effective June 14, 2026.
• Estimated costs: $5.7–$6.4 million (primarily severance, benefits, related cash costs) plus $4.7–$5.0 million in non‑cash stock‑based compensation from accelerated vesting.
• Retention bonuses: up to ~$1.7 million in aggregate cash bonuses payable upon (i) completion of a pre‑BLA meeting with the FDA by Dec 31, 2026 and (ii) FDA confirmation that a BLA filing has been completed and accepted (no later than Sept 30, 2027).
• Leadership changes: Dr. Hussein Sweiti resigned as CMO (effective June 14, 2026); Dr. William Grossman named Interim CMO (part‑time up to 15 hrs/week), will remain on the Board but cease to be an independent director and temporarily stop director compensation; Board’s R&D Committee to be dissolved.
• Timing: Company expects to record the majority of restructuring expenses in the second half of 2026 and emphasized it has retained personnel/resources to pursue key milestones (complete LEGEND Cohort 1, enroll the detalimogene + surfactant cohort, meet with FDA and plan for BLA initiation in H2 2026, and pre‑commercial activities for a potential 2027 launch).

Why It Matters For investors, the filing signals a significant cost‑cutting move intended to extend cash and focus resources on the pivotal LEGEND program and upcoming FDA interactions. The announced restructuring will produce near‑term charges (cash and non‑cash) that will affect reported results and may impact reported cash resources when recorded (majority expected in H2 2026). Leadership changes in the medical/R&D function and dissolution of the R&D Committee are material governance and operational developments to monitor as the company moves toward a potential BLA submission and a possible 2027 commercial timeline.